All News | FDA

Advertising & Promotion

Nov 14, 2021
OPDP Researchers Plan Second Look at Proprietary Names
Nov 6, 2021
California, Oklahoma Courts Find for Manufacturers in Opioid Marketing Cases
Oct 29, 2021
Arizona Settles with Three Physicians Over Insys Speaker Program
Oct 28, 2021
OPDP Researchers To Examine Influence of Targeted Mechanism of Action Claims, Graphics and Disclosures
Oct 21, 2021
FTC Puts Industry on Notice About Endorsements
Oct 14, 2021
FDA Develops Quiz To Promote Bad Ad Program
Oct 7, 2021
Three Advertising and Communication Guidances Gain OMB Information Collection Approval
Sep 30, 2021
Former Insys Sales Rep Pleads Guilty to Fraud Conspiracy Charge Arising From Sham Speaker Program
Sep 30, 2021
Teva Settles Opioid Claims with Louisiana
Sep 17, 2021
Endo Settles New York Cases Involving Opioid Marketing

Good Clinical Practice

Jan 7, 2022
Clinical Investigator Is Issued Warning Letter over Record Retention
Dec 31, 2021
FDA: DHTs Hold Promise But Also Risks for Clinical Trials
Dec 24, 2021
Clinical Investigator Charged with Insider Trading
Dec 17, 2021
HHS, FDA Announce Plans for Clinical Trial Rule Changes
Dec 14, 2021
FDA Final Guidance on Pediatric Studies of Anti-infective Products Adds Recommendations on Safety Data
Dec 3, 2021
OIG Opinion OKs Sponsor Picking Up Medicare Beneficiary Costs in Clinical Trial
Nov 30, 2021
FDA Debars Trial Site Receptionist
Nov 19, 2021
Public Citizen Calls for Disqualification of Two Investigators and IRB
Nov 18, 2021
Biden Nominates Dr. Robert Califf To Head the FDA Again as Commissioner of Food and Drugs
Nov 17, 2021
FDA, NIH Need To Do More To Ensure Trial Result Reporting: JAMA Viewpoint

U.S. Food Labeling

FDA Regulation & Enforcement

Medical Devices

Copyright © Thompson FDA, a division of CBIS. All rights reserved.